Skip to main content
Log in

Malignancy and viability of intraparenchymal brain tumours: Correlation between Gd-DTPA contrast MR Images and proliferative potentials

  • Neuropathological Articles
  • Published:
Acta Neurochirurgica Aims and scope Submit manuscript

Summary

The feasibility of diagnosing the malignancy and viability of intraparenchymal brain tumours using Gd-DTPA, enhanced and unenhanced T1-weighted MRIs was investigated. The relationship between the Gd-DTPA enhancement pattern, the growth fraction (GF) determined by using the anti-bromode-oxyuridine (BrdU) monoclonal antibody, the clinical condition, the proliferative potential and the change of Gd-DTPA enhancement over time was studied.

Forty-five patients with intracranial tumours were studied with the static method of Gd-DTPA MRI. The enhanced effect in Gd-DTPA MRIs was dependent on tumour-cell density, vascularization, necrosis, and dilatation of vascular lumen. Tumour-cells were observed in eighty-seven of eighty-nine specimens taken from areas with Gd-DTPA enhanced MRIs. Seventy-four percent of these specimens (64 of 87) showed a malignancy of more than 5% growth fraction. On the other hand, tumour cells were observed in twentyseven of fifty-six specimens taken from areas with Gd-DTPA unenhanced MRIs. Eighty-five percent of these specimens (23 of 27) showed a malignancy value of less than 5% GF. However, fifteen percent of these specimens showed values between 5 and 15% GF.

In the kinetic study of Gd-MRIs five patients who were in a clinically stable condition and one patient who had radionecrosis showed a constant pattern of enhancement or slightly increased enhancement 30 min after injection compared to 4 min after injection.

Therefore, GD-DTPA MRI can be used effectively in the diagnosis of tumour viability and malignancy after treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Brant-Zawadzki M, Norman D, Newton TH, Kelly WM, Kjos B, Mills CM, Dillon W, Sobel D, Crooks LE (1984) Magnetic resonance of the brain: the optimal screening technique. Radiology 152: 71–77

    PubMed  Google Scholar 

  2. Brasch RC, Weinmann HJ, Wesbey GE (1984) Contrast-enhancement NMR imaging: animal studies using gadoliniumDTPA complex. AJR 142: 625–630

    PubMed  Google Scholar 

  3. Carr DH, Brown J, Bydder GM, Weinmann HJ, Speck U, Thomas DJ, Young IR (1984) Intravenous chelated gadolinium as a contrast agent in NMR imaging of cerebral tumours. Lancet 1: 484–486

    PubMed  Google Scholar 

  4. Carr DH, Brown J, Bydder GM, Steiner RE, Weinmann HJ, Speck U, Hall AS, Young IR (1984) Gadolinum-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients. AJR 143: 215–224

    PubMed  Google Scholar 

  5. Claussen C, Laniado M, Kazner E, Schörner W, Felix R (1985) Application of contrast agents in CT and MRI (NMR): their potential in imaging of brain tumors. Neuroradiology 27: 164–171

    PubMed  Google Scholar 

  6. Claussen C, Laniado M, Schörner W, Niendorf HP, Weinmann HJ, Fiegler W, Felix R (1985) Gadolinium-DTPA in MR imaging of glio-blastomas and intracranial metastases. AJNR 6: 669–674

    PubMed  Google Scholar 

  7. Earnest IV F, Kelly PJ, Scheithauer BW, Kall BA, Cascino TL, Ehman RL, Forbes GS, Axley PL (1988) Cerebral astrocytomas: the topathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166: 823–827

    PubMed  Google Scholar 

  8. Felix R, Schörner W, Laniado M, Niendorf HP, Claussen C, Fiegler W, Speck U (1985) Brain tumors: MR imaging with gadolinium-DTPA. Radiology 6: 855–862

    Google Scholar 

  9. Gado MH, Phelps ME, Coleman ER (1975) An extravascular component of contrast enhancement in cranial computed tomography. Radiology 117: 589–593

    PubMed  Google Scholar 

  10. Graif M, Bydder GM, Steiner RE, Niendorf HP, Thomas DGT, Young IR (1985) Contrast-enhanced MR imaging of malignant brain tumors. AJNR 6: 855–862

    PubMed  Google Scholar 

  11. Houdek PV, Landy HJ, Quencer RM, Sattin W, Poole CA, Green BA, Harman CA, Pisciotta V, Schwade JG (1988) MR characterization of brain and brain tumor response to radiotherapy. Int J Radiat Oncol Biol Phys 15: 213–218

    PubMed  Google Scholar 

  12. Jinnouchi T, Shibata S, Fukushima M, Mori K (1988) Ultrastructure of capillary permeability in human brain tumor — part 6: metastatic brain tumor with brain edema. Neurol Surg (Tokyo) 16: 563–568

    Google Scholar 

  13. Johnson PC, Hunt SJ, Drayer BP (1989) Human cerebral gliomas: correlation of postmortem MR imaging and neuropathologic findings. Radiology 170: 211–217

    PubMed  Google Scholar 

  14. Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA, Kispert DB (1987) Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 62: 450–459

    PubMed  Google Scholar 

  15. Laster DW, Ball MR, Moody DM, Witcofski RL, Kelly DL (1984) Results of magnetic resonance with cerebral glioma; comparison with computed tomography. Surg Neurol 22: 113–122

    PubMed  Google Scholar 

  16. Long DM (1979) Capillary ultrastructure in human metastatic brain tumors. J Neurosurg 51: 53–58

    PubMed  Google Scholar 

  17. McGinnis BD, Brady TJ, New PFJ, Buonanno FS, Pykett IL, De La Paz RL, Kistler JP, Taveras JM (1983) Nuclear magnetic resonance (NMR) imaging of tumors in the posterior fossa. J Comput Assist Tomogr 7: 575–584

    PubMed  Google Scholar 

  18. Mori K, Kurisaka M, Moriki A, Sawada A (1991) Intracranial tumors. In: Mori K (ed) MRI of the central nervous system: a pathology atlas. Springer, Berlin Heidelberg, pp 43–109

    Google Scholar 

  19. Price AC, Runge VM, Allen JH, Partain CL, James AE (1986) Primary glioma: diagnosis with magnetic resonance imaging. CT 10: 325–334

    PubMed  Google Scholar 

  20. Randell CP, Collins AG, Young IR, Haywood R, Thomas DJ, McDonnel MJ, Orr JS, Bydder GM, Steiner RE (1983) Nuclear magnetic resonance imaging of posterior fossa tumors. AJNR 4: 1027–1034

    Google Scholar 

  21. Runge V, Schorner W, Niendorf HP, Laniado M, Koehler D, Claussen C, Felix R, James AE (1985) Initial evaluation of gadolinium-DTPA for contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 3: 27–35

    PubMed  Google Scholar 

  22. Sage MR (1982) Blood-brain barrier: Phenomenon of increasing importance to the imaging clinician. AJNR 3: 127–138

    Google Scholar 

  23. Tokano S, Yoshii Y, Nose T (1991) Ultrastructure of glioma vessel: morphometric study for vascular permeability. Brain Nerve (Tokyo) 43: 49–56

    Google Scholar 

  24. Weinmann HJ, Brasch RC, Press WR, Wesbey GE (1984) Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR 142: 619–624

    PubMed  Google Scholar 

  25. Yoshii Y, Maki Y, Tsuboi K, Tomono Y, Nakagawa K, Hoshino T (1986) Estimation of growth fraction in human central nervous system tumors by bromodeoxyuridine. J Neurosurg 65: 653–659

    Google Scholar 

  26. Zimmerman RA, Bilaniuk LT, Goldberg HI, Grossman RI, Levine RS, Lynch R, Edelstein W, Bottomley P, Redington R (1984) Cerebral NMR imaging: early results with a 0.12T resistive system. AJNR 5: 1–7

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoshii, Y., Komatsu, Y., Yamada, T. et al. Malignancy and viability of intraparenchymal brain tumours: Correlation between Gd-DTPA contrast MR Images and proliferative potentials. Acta neurochir 117, 187–194 (1992). https://doi.org/10.1007/BF01400619

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01400619

Keywords

Navigation